Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29113545 | 0.87 | LRRK2 (0.36) | LRRK2MAPK1JAK1JAK2JAK3 | |
| SCHEMBL29113535 | 0.83 | LRRK2 (0.40) | LRRK2CYP1A2MAPK1FLT4JAK1 | |
| SCHEMBL26980380 | 0.83 | LRRK2 (0.44) | LRRK2CYP1A2MAPK1FLT4JAK1 | |
| SCHEMBL29929758 | 0.83 | LRRK2 (0.44) | LRRK2CYP1A2MAPK1FLT4JAK1 | |
| SCHEMBL29929286 | 0.81 | JAK3 (0.52) | JAK3 | |
| SCHEMBL26979886 | 0.81 | JAK3 (0.52) | JAK3 | |
| SCHEMBL29113556 | 0.79 | JAK2 (0.46) | LRRK2JAK2JAK3SYK | |
| SCHEMBL29929752 | 0.79 | CCNT1 (0.41) | LRRK2CYP1A2MAPK1JAK1JAK2 | |
| SCHEMBL26980190 | 0.79 | CCNT1 (0.41) | LRRK2CYP1A2MAPK1JAK1JAK2 | |
| SCHEMBL29113572 | 0.79 | JAK3 (0.38) | FLT4JAK1JAK2JAK3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117136184-A | Aminopyrimidine compounds and methods of use thereof | 泰拉生物科学公司 | 2023-11-28 | — | — | CN | disclosed |